

# NeuroCure Therapeutics

## Overview

NeuroCure Therapeutics is an early-stage biotech company focused on developing targeted therapies for glioblastoma multiforme (GBM), one of the most aggressive brain cancers. Our proprietary NeuroBridge™ platform delivers small-molecule inhibitors across the blood-brain barrier using a novel receptor-mediated transport system. This approach addresses a critical challenge in neuro-oncology by enabling effective drug delivery to tumor sites while minimizing systemic toxicity. The platform is designed for adaptability, allowing expansion into other CNS malignancies and neurodegenerative disorders, creating a robust pipeline opportunity.

## Problem

GBM accounts for nearly 50% of malignant brain tumors and carries a median survival of less than 15 months. Current treatments, including surgery, radiation, and chemotherapy, offer limited benefit due to poor drug penetration across the blood-brain barrier and rapid tumor recurrence. There is an urgent need for therapies that can effectively reach the tumor site and disrupt key survival pathways.

## Solution

NeuroBridge™ enables targeted delivery of kinase inhibitors directly to GBM cells by exploiting receptor-mediated transport mechanisms. This precision approach enhances drug accumulation in tumor tissue while reducing off-target effects. By overcoming the blood-brain barrier challenge, NeuroCure offers a transformative solution for GBM and other CNS diseases.

## Market

GBM affects approximately 13,000 patients annually in the United States and over 120,000 worldwide. The estimated addressable market for GBM therapies exceeds \$3 billion annually, with additional opportunities in other CNS cancers and neurodegenerative conditions pushing the potential market beyond \$10 billion. Global neuro-oncology

therapeutics are projected to grow at a CAGR of 12%, driven by unmet clinical needs and technological advancements.

## Clinical Need

Current GBM treatments fail to provide durable responses, and no approved therapies effectively overcome the blood-brain barrier. NeuroBridge™ addresses this gap by enabling targeted delivery of potent inhibitors to tumor sites, improving efficacy and patient outcomes.

## Competition

Existing GBM therapies include temozolomide and tumor-treating fields, which offer modest survival benefits. Emerging approaches such as CAR-T and oncolytic viruses face delivery and safety challenges. NeuroCure's differentiated platform positions it as a first-in-class solution for effective CNS drug delivery.

## Team

CEO: Dr. Michael Torres, PhD (neuropharmacology, ex-Novartis). CSO: Dr. Aisha Rahman, PhD (blood-brain barrier biology, Harvard). Advisors include Dr. Emily Chen (Dana-Farber) and Dr. Raj Patel (Johns Hopkins), providing expertise in neuro-oncology and translational research.

## Capital Raised & Seeking

Raised: \$1M (founders + NIH grant). Seeking: \$6M Seed Round to advance NeuroBridge™ through IND-enabling studies and initiate Phase I trials.

## Use of Funds

Funds will be allocated to optimize NeuroBridge™ formulation, complete GLP toxicology, and prepare IND submission for GBM clinical trials. Additional resources will support regulatory engagement and strategic partnerships.

## Timeline

18 months to IND submission.